ArticleOncotarget2017
Vitamin D increases programmed death receptor-1 expression in Crohn's disease.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Vitamin D for the treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023Pooled it
- Trial
- The 1α,25-dihydroxyvitamin D3 modulates T cell activation and immune checkpoint pathways in human T cells.Frontiers in immunology · 2026Article
- Association of Vitamin D Status with Immune Markers in a Cohort of Healthy Adults.The Journal of nutrition · 2025Article
- Vitamin D in Cutaneous T-Cell Lymphoma.Cells · 2024Review
- Review
- Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors.Life (Basel, Switzerland) · 2022Review
- 1α,25(OH)Journal for immunotherapy of cancer · 2022Article
- Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells.Frontiers in microbiomes · 2022Review
- Article
- Differential Response of Lung Cancer Cells, with Various Driver Mutations, to Plant Polyphenol Resveratrol and Vitamin D Active Metabolite PRI-2191.International journal of molecular sciences · 2021Article
- Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors.Archives of dermatological research · 2021Review
- Retinoic Acid Modulates Hyperactive T Cell Responses and Protects Vitamin A-Deficient Mice against Persistent Lymphocytic Choriomeningitis Virus Infection.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Relevance of Vitamin D in Melanoma Development, Progression and Therapy.Anticancer research · 2020Review
- Micronutrient Absorption and Related Outcomes in People with Inflammatory Bowel Disease: A Review.Nutrients · 2019Review
- Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy.American journal of translational research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D modulates inflammation in Crohn's disease (CD). Programmed death (PD)-1 receptor contributes to the maintenance of immune tolerance. Vitamin D might modulate PD-1 signalling in CD.
aimTo investigate PD-1 expression on T cell subsets in CD patients treated with vitamin D or placebo.
methodsWe included 40 CD patients who received 1200 IU vitamin D3 for 26 weeks or placebo and eight healthy controls. Peripheral blood mononuclear cells (PBMCs) and plasma were isolated at baseline and week 26. The expressions of PD-1, PD-L1, and surface activation markers were analysed by flow cytometry. Soluble PD-1 plasma levels were measured by ELISA.
resultsPD-1 expression upon T cell stimulation was increased in CD4+CD25+int T cells in vitamin D treated CD patients from 19% (range 10 - 39%) to 29% (11 - 79%)(p = 0.03) compared with placebo-treated patients. Vitamin D treatment, but not placebo, decreased the expression of the T cell activation marker CD69 from 42% (31 - 62%) to 33% (19 - 54%)(p = 0.01). Soluble PD-1 levels were not influenced by vitamin D treatment.
conclusionsVitamin D treatment increases CD4+CD25+int T cells ability to up-regulate PD-1 in response to activation and reduces the CD69 expression in CD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.